DSP-2230

DSP-2230 is the orally active inhibitor for voltage-gated sodium channel that inhibits Nav1.7-, Nav1.8-, and Nav1.9-derived sodium currents with IC50s of 7.1 μM, 11.4 μM and 6.7 μM, respectively. DSP-2230 can be used to improve neuropathic pain[1][2][3][4].

Product Specifications

CAS Number

[1233231-30-5]

Product Name Alternative

ANP-230

UNSPSC

12352005

Target

Sodium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

COVID-19-immunoregulation

Field of Research

Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/dsp-2230.html

Concentration

10mM

Purity

98.33

Solubility

DMSO : ≥ 100 mg/mL

Smiles

C[C@H](NCC1=NC2=CC=C(OC3=CC(F)=C(F)C(F)=C3)N=C2N1C4CCC4)C(N)=O

Molecular Formula

C20H20F3N5O2

Molecular Weight

419.40

References & Citations

[1]Bagal SK, et al. Voltage gated sodium channels as drug discovery targets. Channels (Austin) . 2015;9 (6) :360-6.|[2]Sara Sabina Hadida-Ruah, et al. Sulfonamides as modulators of sodium channels.|[3]Okuda H, et al., Reduced pain sensitivity of episodic pain syndrome model mice carrying a Nav1.9 mutation by ANP-230, a novel sodium channel blocker. Heliyon. 2023 Apr 14;9 (4) :e15423.|[4]Kamei T, et al., Unique electrophysiological property of a novel Nav1.7, Nav1.8, and Nav1.9 sodium channel blocker, ANP-230. Biochem Biophys Res Commun. 2024 Aug 20;721:150126.